CDK4 and breast carcinoma: For example, breast cancers that have become resistant to anti-estrogen therapies (that inhibit cyclin D/CDK4 activity) present an amplification of cyclin E2, suggesting that the presence of cyclin E2 could be a potential mechanism of endocrine resistance.